[ @entity176 in XXXX ].

@entity1 @entity174 @entity14577 @entity5298 @entity5299 @entity460 @entity176
@entity176 is one of the first-line agents with proven anti- @entity174 activity used in the therapy of @entity14577 . Its mechanism of action makes it, however, different from other drugs, since it simultaneously stimulates two reverse processes: bone formation and bone resorption. The action of the agent depends on various mechanisms, including the activation of @entity460 receptors, localised on osteoblasts and osteoclasts, and on the influence on the @entity5299 / @entity5298 system. The drug effectively prevents spinal, hip and extravertebral fractures. The agent's anti- @entity174 efficacy within the spine does not depend on the @entity1 's age, or on base BMD values, or on the concentration of bone metabolism markers. As to the anti- @entity174 efficacy in the hip, it concerns @entity1 with an increased @entity174 risk. @entity176 increases bone mineral density within the lumbar spine and the hip, decreases the concentrations of bone resorption markers, and increases the concentrations of bone formation markers. The drug is administered in a daily 2.0 g oral dose. This paper presents indications to therapy with @entity176 , specifying also its side effects and contraindications. We compare the anti- @entity174 efficacy of @entity176 to the efficacy of other agents of proven anti- @entity174 activity, based on published clinical studies.
